Introduction
It is estimated that the incidence of cancer in humans increases between 10 3 ± 10 7 times with advancing age (Miller, 1980) . Such clinical observations prompted the multi-hit hypothesis of oncogenesis, which states that cellular transformation is due to an accumulation of somatic mutations. A paradigm for this hypothesis is the development of colorectal cancer, where there have been described seven independent genetic alterations that have been associated with progression to malignancy (Kinzler and Vogelstein, 1996) . Among the mutations required for colorectal oncogenesis are the activation of RAS and inactivation p53, two of the most frequently mutated genes in human cancer (Baker et al., 1990; Jen et al., 1994) .
Data from model tumorigenic systems and cellular transformation studies support the concept that multiple genetic alterations are necessary for generation of the malignant phenotype. Activation of RAS by itself is insucient to induce transformation in primary rat embryo ®broblasts. However when co-expressed with a cooperating oncogene such as c-MYC or in a cellular environment de®cient in key tumor suppressors such as p53 or p16, RAS is able to promote cellular transformation (Land et al., 1983; Serrano et al., 1997) . Individual oncogenic stimuli can actually be toxic to cells. Forced expression of c-MYC in a normal cellular background leads to apoptosis but is tolerated in cells lacking p16 or p53 (Zindy et al., 1998) . These data suggest that aberrant expression or activation of any single gene is insucient to mediate cellular transformation.
In contrast to most adult epithelial malignancies, an increasing proportion of pediatric cancers carry tumorspeci®c chromosomal abnormalities. It is thought that the altered gene products resulting from these genomic rearrangements play dominant oncogenic roles. The EWS/ETS gene fusions found in Ewing's sarcoma/ primitive neuroectodermal tumor (ES/PNET) are representative of a class of chimeric oncogenes that have the biochemical attributes of aberrant transcription factors (May et al., 1993;  for review see Kovar, 1998) . As a result of chromosomal translocation, the N-terminus of EWS is fused to the C-terminus of one of ®ve potential ETS genes. In approximately 90% of ES/PNETs a t(11;22) rearrangement results in the generation of the EWS/FLI1 fusion protein that when expressed in NIH3T3 cells promotes anchorage independent growth and accelerated tumorigenesis .
The demonstration of the oncogenic eects and even the stable expression of EWS/FLI1 has thus far has been limited to the NIH3T3 cells. This behavior is similar to that of activated RAS, which is also able to transform NIH3T3 cells in single step fashion but requires additional complementing mutations to transform non-immortalized primary cells (Hahn et al., 1999; Lowry et al., 1978) . The inability to achieve stable expression in cells other than NIH3T3 ®bro-blasts suggests that expression of EWS/FLI1 is also reliant upon such pre-existing complementary mutations. We now show that EWS/FLI1 induces growth arrest and apoptosis in normal primary mouse embryo ®broblasts (MEFs). These eects are attenuated in genetically altered MEFs with defects in the p19 ARF -p53 cell cycle regulatory pathway allowing for stable expression of EWS/FLI1. Genetically altered MEFs expressing EWS/FLI1 are only partially tumorigenic in immunode®cient mice requiring further genetic alterations such as expression of SV40 virus T antigen to generate the complete tumorigenic phenotype.
Results

Normal MEFs do not support stable EWS/FLI1 expression
Though the oncogenic eects of EWS/FLI1 have been clearly documented in NIH3T3 cells, it has not been possible to achieve similar results in other cell backgrounds. This is due to the inability to stably transduce EWS/FLI1 into other immortalized cell lines representing mesenchymal (Rat-1), epithelial (HeLa) and neuroectodermal (NCM-1) lineages (data not shown). Mouse embryonic ®broblasts (MEFs) were used to study this phenomenon further. Considering that NIH3T3 cells are derived from primary MEFs, we reasoned MEFs might be a close starting point to genetically de®ning a cell background that would sustain stable expression of EWS/FLI1.
Low passage wild type MEFs were infected with replication de®cient retroviral stocks of approximately equal titer containing either EWS/FLI1 or Green Fluorescence Protein (GFP) as control. Forty-eight hours after infection, 495% of MEFs infected expressed GFP as determined by¯uorescence-activated cell sorting (FACS) analysis, indicating that virtually all cells were productively infected (data not shown). To determine the stability of EWS/FLI1 protein expression, protein extracts of transduced MEFs were harvested at varying time points and immunoblot analyses were performed using polyclonal anti-FLI1 antibody (Figure 1 ). At two days, EWS/FLI1 protein was detected at levels comparable to 3T3 derived EWS/ FLI1 tumor cell lines, indicating ecient transduction of the fusion gene and levels of protein expression that are permissive in 3T3 cells. However no EWS/FLI1 protein was detectable at seven days indicating a loss of EWS/FLI1 expression possibly due to a toxic eect in normal MEFs.
EWS/FLI1 inhibits the growth of MEFs
One explanation for our inability to achieve stable expression of EWS/FLI1 in normal MEFs is that EWS/FLI1 may inhibit cellular growth in this particular context. Such an eect has also been seen with forced expression of other oncogenic proteins such as c-MYC or activated RAS in normal MEFs (Serrano et al., 1997; Zindy et al., 1998) . To examine the eect of EWS/FLI1 on the growth of normal MEFs, proliferation and cell viability assays were performed.
As before, wild type MEFs were infected with retrovirus containing either GFP or EWS/FLI1 and at varying time points cells were harvested and enumerated. Transduction eciency was con®rmed using FACS for GFP infected cells and anti-FLI1 immunoblot for EWS/FLI1 infected cells (data not shown). In sharp contrast to GFP MEFs, transduction of EWS/FLI1 into MEFs resulted in an immediate cessation of cell growth followed by a slow decay in cell number over a period of 1 week (Figure 2a) . By day 8 of the proliferation assay MEFs expressing GFP have sixfold more cells than MEFs expressing EWS/ FLI1, furthermore MEFs expressing EWS/FLI1 decrease in overall number from the initial infection. Morphologic examination of EWS/FLI1 MEFs 2 days post infection revealed two populations of cells: (a) a majority population that consisted of nonadherent nonviable pyknotic cells and (b) small numbers of adherent enlarged cells with abundant cytoplasm (Figure 2c) .
As a quantitative measure of cell viability, MEFs transduced with either EWS/FLI1 or empty vector were assayed for the ability to exclude propidium iodide 3 days post-infection. Nonviable cells lose the ability to exclude propidium iodide and can be detected by FACS. By this method approximately two thirds of EWS/FLI1 MEFs were nonviable as compared to less than 10% of MEFs transduced with empty vector (Figure 2b ). In order to determine the cell cycle kinetics of MEFs infected with EWS/FLI1 that were viable at time points beyond 2 days, cell cycle and BrdU incorporation assays of MEFs 6 days post-infection Figure 1 Expression of transduced EWS/FLI1 in normal mouse embryonic ®broblasts (MEFs). Immunoblot analysis using rabbit polyclonal antisera towards epitopes at the C-terminus of FLI1. Detection is limited to exogenous EWS/FLI1 since endogenous murine FLI1 is not expressed in these lines 
Transduction of EWS/FLI1 induces apoptosis in MEFs
Retroviral transduction of EWS/FLI1 into normal MEFs elicits growth arrest and increased cell death. Increased cell death may be due to an induction of apoptosis by EWS/FLI-1. Forced expression of c-MYC generates an apoptotic response in cells grown in low serum (Evan et al., 1992; Zindy et al., 1998) . It is possible that EWS/FLI1 could be behaving in an analogous fashion under normal plating conditions. Sub-G1 FACS analysis was used to quantitate the proportion of apoptotic cells in MEFs transduced with EWS/FLI1 or empty vector. MEFs were infected with high titer retroviruses and then collected 48 h later, stained with propidium iodide and the number of cells with hypodiploid DNA content was determined using FACS. Approximately one third of EWS/FLI1 MEFs demonstrated hypodiploidy while MEFs transduced with empty vector had only 4% hypodiploidy ( Figure  3a) .
Because of its central role in apoptotic signaling cascades, activation of caspase 3 was used as a biochemical marker for apoptosis in MEF populations (Thornberry and Lazebnik, 1998; Villa et al., 1997) . Two days after retroviral transduction with either EWS/FLI1 or empty vector, whole cell protein lysates were prepared and incubated with a¯uorogenic caspase 3 substrate, Ac-DEVD-AMC. Caspase 3 cleavage of this substrate was quantitated by FACS. EWS/FLI1 MEFs demonstrated a reproducible 14-fold increase in caspase 3 activity when compared to MEFs transduced with empty vector (Figure 3b ). Taken in sum, these data indicate that EWS/FLI1 elicits an apoptotic response in normal MEFs.
Interruption of the p19
ARF -p53 pathways permits stable expression of EWS/FLI1 in MEFs
Considering the toxic eect of EWS/FLI1 on normal MEFs, it seemed likely that additional genomic events were necessary for stable EWS/FLI1 expression in MEFs. EWS/FLI1 can be stably expressed in NIH3T3 cells which are derived from immortalized MEF clones. It has been shown that during the immortalization process, MEFs acquire either inactivation of the p53 gene or genomic loss at the p16 locus (Kamijo et al., 1997; Zindy et al., 1997) . In addition approximately 30% of primary ES/PNET tumor samples contain a homozygous deletion of the p16 locus that encodes the two cell cycle regulatory genes, p16
INK4A and p19 ARF (Kovar et al., 1997) . These observations suggested that disruption of the p16 or p53 loci might render cells tolerant to stable expression by EWS/FLI1. To test this hypothesis, MEFs that harbored homozygous deletions in p16 or p53 were transduced with EWS/FLI1 or GFP. Two dierent mutant p16 MEF populations were employed: (a) p167/7 that had a homozygous deletion in exon 2 that is shared by both p16
INK4A and p19 ARF (Serrano et al., 1996) and (b) ARF7/7 cells that have a speci®c mutation knocking out p19 ARF but not p16 INK4A (Kamijo et al., 1997) . Use of the p19ARF speci®c knockout allowed us to determine if loss of ARF function alone was sucient for EWS/FLI1 expression or if loss of both p19 ARF and p16
INK4a was required. P19 ARF has a signi®cant eect on p53 that could be explicitly assessed using p53 null MEFs. As a group these mutant populations would help map which pathways were involved in EWS/FLI1 intolerance in MEFs.
As before, MEFs were transduced with EWS/FLI1 or GFP retroviruses and cell aliquots were harvested at varying time points for proliferation and immunoblot assays. The growth pro®le of p167/7 MEFs expressing EWS/FLI1 revealed an initial phase of growth suppression at 2 and 4 days, but by day 6 the rate of growth was essentially the same as the GFP control cell line (Figure 4a ). The growth kinetics of ARF7/7 and p537/7 MEFs expressing EWS/FLI1 had similar properties as p167/7 MEFs expressing EWS/FLI1 ( Figure 4a ) Protein extracts were harvested at weekly intervals post-infection and subjected to immunoblot analysis using anti-FLI1 antisera (Figure 4b ). EWS/FLI1 protein was readily detected in EWS/FLI1 transduced p167/7, p537/7, and ARF7/7 MEFs at 1 and 2 weeks after retroviral infection. EWS/FLI1 expression levels were monitored as far as 4 weeks after transduction and without any decrement in expression (data not shown).
Interruption of the p19 ARF -p53 pathway attenuates EWS/ FLI1 induced apoptosis A common link between the three MEF populations that sustain stable expression of EWS/FLI1 is that they all have an interruption of the p19 ARF -p53 cell cycle regulatory pathway. This pathway has been shown to play a central role in promoting cell cycle arrest in response to aberrant mitogenic signals (Serrano et al., 1997; Zindy et al., 1998) . This would suggest that the mutant MEF populations may not have the same apoptotic response to EWS/FLI1 that normal MEFs display.
To quantitate cell death and apoptosis rates in mutant MEFs, propidium iodide exclusion and sub-G1 analyses were performed on polyclonal populations 48 h after retroviral transduction with either EWS/FLI1 or empty vector ( Figure 5 ). Transduction of EWS/FLI1 induced apoptosis in mutant p16 and ARF MEFs as compared to infection with empty vector retroviruses but not in p53 de®cient MEFs. However, when compared to normal MEFs, apoptosis rates were signi®cantly decreased in both p167/7 and ARF7/7 MEFs by at least 40%. Given the experimental variation ( Figure 5 ), there does not appear to be a signi®cant dierence in apoptosis to EWS/FLI1 between p16 and ARF de®cient MEFs. Global cell death rates followed this same trend. EWS/ FLI1 transduction promoted cell death in all mutant MEF populations.
Expression of HPV-E7 renders normal primary human fibroblasts tolerant to EWS/FLI1
Stable expression of EWS/FLI1 is achievable in p167/ 7 MEFs that have lost both p16 INK4A -Rb and p19 ARF -p53 cell cycle regulatory pathways and in ARF7/7 MEFs that have lost only p19 ARF -p53 function. While it is likely that the observed tolerance to EWS/FLI1 expression is a direct result of these speci®c pathways, the participation of other latent mutations cannot be conclusively ruled out. In addition, it is dicult to determine whether our observations are limited to murine embryo ®broblasts, which can have signi®cant physiologic dierences to their human counterparts. In order to approximate in a human system the conditions present in p16 and p53 de®cient MEFs, the human papilloma virus (HPV) E7 and E6 genes were used in conjunction with human umbilical cord ®broblasts. The HPV-E7 oncoprotein directly binds to Rb but is also able to inhibit p53 mediated cell cycle arrest through direct inhibition of p21 (Dyson et al., 1989; Davies et al., 1993; Funk et al., 1997; . Ectopic expression of HPV-E7 therefore creates a genetic condition similar to that of the p16 null MEFs. The HPV-E6 oncoprotein directly binds and inhibits p53 function mimicking the p53 de®cient MEFs (Werness et al., 1990) .
Primary human umbilical cord ®broblasts were sequentially infected with retroviruses containing TERT (the catalytic subunit of telomerase) and HPV-E7, or TERT and HPV-E6. After brief antibiotic selection, RNA was harvested from a cell aliquot and Northern analysis was used to con®rm expression of TERT, HPV-E6, and HPV-E7 (Figure 6a ). Cells transduced with the TERT HPV-E7 demonstrated an increase in growth rate over untransduced umbilical cord ®broblasts and could be passed easily in tissue culture. In contrast TERT HPV-E6 cells had no apparent change in growth rate and began to show signs of senescence with serial passage. Cell populations expressing TERT and HPV-E7 or TERT and HPV-E6 were next infected with retroviruses containing EWS/FLI1 or GFP. After further selection with a second antibiotic, cell protein extracts were prepared and expression of EWS/ FLI1 was assessed by immunoblot. EWS/FLI1 protein was readily detected in the TERT and HPV-E7 expressing cell lines at 1 and 2 weeks (Figure 6b ). Under these conditions, EWS/FLI1 was stably expressed in primary human ®broblasts for up to 4 weeks post-selection with no decrement in protein levels (data not shown). On the other hand, in cell expressing TERT and HPV-E6, EWS/FLI1 protein was not detected at the 1 and 2 week time points (data not shown). Control experiments, including transduction of EWS/FLI1 into cells containing only TERT, HPV-E6, or HPV-E7 yielded no cell populations with detectable EWS/FLI1 protein (data not shown).
Additional genetic alterations are necessary for consistent induction of EWS/FLI1 tumorigenesis in MEFs EWS/FLI1 accelerates tumorigenesis in NIH3T3 cells although the complete complement of genetic mutations in this cell line is unknown. Stable expression of EWS/FLI1 in p16, p53, or ARF de®cient MEFs allows for the investigation of the transforming potential of EWS/FLI1 in a genetically de®ned background. Considering that 30% of Ewings tumors contain a homozygous deletion of p16, we reasoned that loss of function mutations in this locus could enhance the oncogenic eects of EWS/FLI1.
To determine the tumorigenic potential of EWS/ FLI1 transduced MEF populations, cells were injected subcutaneously into SCID mice and tumor formation was monitored over a period of 100 days. No tumors were evident in mice that received EWS/FLI1 ARF7/ 7 or EWS/FLI1 p537/7 MEFs (Table 1) . However 2/10 mice injected with EWS/FLI1 p167/7 MEFs developed tumors. These tumors demonstrated a round cell histology that resembled that seen in ES/PNET tumors (data not shown).
The observation that tumors were seen in only a minority population of EWS/FLI1 p167/7 MEFs suggested that a subpopulation had acquired additional genetic mutations necessary to promote in vivo growth. To test this hypothesis, the simian virus large T antigen (SV40 large T) was used to provide an additional oncogenic stimulus. SV40 large T promotes cellular transformation through several mechanisms including (a) inhibition of p53, (b) binding to the Rb family of proteins and (c) other less well characterized pathways (Zalvide et al., 1998; Damania et al., 1998) .
P16, ARF and p53 de®cient MEFs were sequentially infected with retroviruses containing EWS/FLI1 or GFP followed by SV40 large T. After brief antibiotic selection, cell aliquots were harvested and expression of SV40 large T and EWS/FLI1 was con®rmed through Northern and immunoblot analyses respectively (Figure 7b ). Subcutaneous injection into SCID mice with the p167/7 MEF cell lines expressing SV40 Large T led to tumor formation in 8/8 cell lines expressing EWS/FLI1 and 7/8 cell lines expressing GFP. While SV40 Large T supported tumor formation in p167/7 MEFs expressing GFP, The average rate of tumor formation was 45 days for EWS/FLI1 expressing cell lines, whereas the GFP cell lines that supported tumor formation had a mean rate of 68 days. (Table 1 , Figure 7a ) Furthermore, the tumors produced by the EWS/FLI1 cell lines resembled the small round histology that is characteristic of ES/PNET, while the tumors produced by the GFP cell lines resembled the a spindle like morphology, that is not consistent with ES/PNET tumors (data not shown).
There was no dierence in the rate of tumor formation in p53 null MEFs co-expressing SV40 Large T and either GFP or EWS/FLI1 (data not shown). Therefore p53 null MEFs could not be used to assess the tumorigenic eects of EWS/FLI1. The ARF7/7 cell lines expressing SV40 Large T were a more stringent model for EWS/FLI1 induced tumorigenesis. ARF7/7 MEFs did not support tumor formation by SV40 alone, yet the addition of EWS/FLI1 to these cells lines was sucient to produce tumors in 6/8 mice at a mean rate of 40 days (Table 1, Figure 7a ) and resembled the small round morphology characteristic of ES/PNET (data not shown). Expression analysis of explant tumor cell lines, revealed that the level of EWS/FLI1 protein detected in tumor explants was approximately the same as that seen in input MEF populations (Figure 7b ). These data indicate that in this system further genetic perturbation, outside of loss of p16 or p19 ARF , is required to induce EWS/FLI1 tumorigenesis.
Discussion
EWS/FLI1 exerts a toxic eect on normal MEFs in an apparent biphasic manner: an initial wave of apoptosis is followed by growth arrest of the surviving cells. After weeks in culture viable cells eventually grow out, but EWS/FLI1 protein is undetectable in these populations. Dierences in cell cycle and the incorporation of BrdU are not apparent in EWS/FLI1 and GFP MEF cell lines, due perhaps to the outgrowth of non-infected cells. It is possible that part of the early apoptosis is secondary to the stress of retroviral infection coupled with high levels of EWS/FLI1 protein. Nevertheless, apoptosis rates are signi®cantly reduced in mutant MEFs particularly those that have lost p19
ARF or p53. While EWS/FLI1 still induced some early phase cell death, none of the mutant MEF populations experienced the later phase growth arrest and it was therefore possible to establish longterm EWS/FLI1 expressing populations. Such data illustrates a mechanism by which complementary mutations facilitate the establishment of EWS/ETS fusions. Furthermore, this observation is consistent with the eects of activated RAS and c-MYC, where in normal MEFs these genes induce premature senescence and apoptosis, respectively, but do not in p16 or p53 de®cient MEFs (Serrano et al., 1997; Zindy et al., 1998) .
The cell of origin of ES/PNET is unknown. In both primary tumors and derived cell lines ES/PNETs display both neural and mesenchymal characteristics that has lead to the theory that the cell of origin may be a pluripotential precursor that could dierentiate along both lineages (Morrison et al., 1999; Teitell et al., 1999) . It is possible that some of the toxicity of EWS/ FLI1 seen in normal MEFs may result simply from trying to express the fusion gene in a more dierentiated or inappropriate cell type. However, our inability to establish stable EWS/FLI1 expression in immortalized neuroectodermal and epithelial cell lines argues against EWS/FLI1 cellular toxicity being strictly lineage speci®c. In addition the inability to transduce EWS/FLI1 into primary murine bone marrow cells (data not shown) as well as the diculty in creating EWS/FLI1 transgenic models (G Grosveld, personal communication), may re¯ect EWS/FLI1 toxicity in undierentiated progenitor cells.
The fact that 30% of primary ES/PNET tumor specimens show homozygous loss of p16 validates our use of p167/7 or ARF7/7 MEFs to study the apparent relationship between EWS/FLI1 and the p16 locus. While loss of p16 is able to attenuate the apoptotic eects of EWS/FLI1 and is sucient for stable expression of the protein, it does prompt the question of how the 70% of ES/PNETs without apparent p16 deletion can tolerate stable expression of EWS/ETS fusion genes. It is possible that loss of p16 is necessary for EWS/FLI1 cells to grow in tissue culture. However, while the majority of ES/PNET tumor cell lines have inactivating mutations of either p16 or p53, not all do (Kovar et al., 1997) . This argues The rate of tumor formation for p167/7+SV40 Large T MEFs expressing EWS/FLI1 diers from that of the p167/7+SV40 Large T cell line expressing GFP at a P value of 50.01, indicating that such dierences are statistically signi®cant. Statistical analysis was not applicable to the ARF7/7+SV40 Large T cell lines, due to the lack of signi®cant tumor formation in the GFP expressing cell lines. (**) denotes that such measurements are not applicable to the given samples Oncogene Loss of p16 complements EWS/FLI1 transformation B Deneen and CT Denny that other genetic mechanisms may be active. While p16 may not be deleted in 70% of ES/PNETs, it is possible that epigenetic phenomenon such as genomic methylation may play a role in p16 down regulation. Transcriptional down regulation of the p16 locus through promoter hypermethylation is found in both colorectal and bladder cancer (Esteller et al., 2000; Gonzalgo et al., 1998) . Alternatively, ES/PNETs may harbor mutations in other genes that may be mediating the EWS/FLI1 growth arrest eect. Attenuation of the apoptotic eects of EWS/FLI1 may not be restricted to the loss of p16, thus other unde®ned complementary mutations that eect apoptosis may be present in Ewings tumors. In MEFs loss of either p19 ARF or p53 is sucient for stable expression of EWS/FLI1. However, primary human ®broblasts expressing HPV-E6, a p53 inhibitor, did not tolerate EWS/FLI1. This apparent discrepancy may re¯ect the imprecision of trying to inhibit p53 by HPV-E6 as opposed to genetically removing p53 altogether as in the MEF experiments. In addition, these diering responses probably indicate underlying physiologic dierences between murine and human ®broblasts. Considering the eect of HPV-E7 on the ability to achieve stable EWS/FLI1 expression, it appears that human ®broblasts require abrogation of the p16
INK4A
-Rb pathway in addition to the p19 ARF -p53 pathway that is sucient for MEFs. As noted above, a subset of ES/PNETs harbor homozygous mutations at the p16 locus that would functionally impact both pathways.
Though loss of p16, p53, or ARF is sucient to achieve stable EWS/FLI1 expression in MEFs, it is not sucient to render these cells tumorigenic in immunode®cient mice. The observation that a minority of p16 de®cient MEFs expressing EWS/FLI1 formed tumors suggests that additional genetic alterations are required for in vivo tumor growth. In general p16 null MEFs appeared more tumorigenic than ARF null MEFs in response to a number of stimuli including EWS/FLI1. The majority (7/8) of mice injected with p167/7 MEFs expressing SV40 Large T formed tumors while only 1/8 mice that received ARF null MEFs with SV40 Large T had tumor growth. This observation indicates that there is a dierence between these two MEF populations that is independent of EWS/FLI1 and may re¯ect abrogation of additional genetic pathways in p16 null MEFs that are intact in ARF null cells. Though SV40 large T is a known inhibitor of p53 and Rb function, which would be partially redundant in particular mutant MEFs, it seems likely that it is also contributing additional oncogenic stimuli. It has been shown that SV40 Large T is able to transcriptionally activate target genes relevant to cellular proliferation (Moens et al., 1997; Damania et al., 1998) , suggesting that the oncogenic eects of SV40 Large T extend to cellular pathways beyond p53 and Rb. These eects are indicated by the observation that SV40 Large T is able to transform primary human ®broblasts harboring activated RAS but co-expression of HPV-E6 and HPV-E7 will not transform these cells (Hahn et al., 1999; Kiyono et al., 1998) . It is possible that similar SV40 large T pathways independent of p53 and Rb, that complement RAS mediated transformation may also be involved in EWS/FLI1 transformation. It may be possible to further de®ne EWS/FLI1 complementing pathways using SV40 Large T antigen mutants with de®ned biological and biochemical characteristics (Martinez et al., 1991; Gjoerup et al., 2000) . It will be important to prove the signi®cance of these pathways in the context of ES/PNET cells.
In the development of ES/PNET we have further delineated two genetic steps on the path to oncogenesis. At some point, chromosomal translocation occurs fusing EWS to an ETS partner. An additional genetic mutation is also needed to suppress the growth arrest eects of the EWS/ETS fusion. Whether this comes before or after the translocation is unclear and may depend on the biology of the ES/PNET cell of origin. (Figure 8 ) If the cell of origin has a dierentiated phenotype such as MEFs, a pre-existing, growth arrest suppressing mutation would be required. Alternatively undierentiated cell populations may be tolerant of EWS/ETS to a sucient extent to allow for subsequent genetic mutations. Further resolution of these two alternatives requires better model systems to assay EWS/ETS tumorigenicity. While further genetic perturbation may be required for cellular transformation outside of p16 and EWS/ETS fusions, these pathways remain unde®ned. From a purely pragmatic view, the ability to stably express EWS/ETS proteins in a de®ned genetic background will help in the development of these systems.
There is an increasing eort to correlate the molecular genotype of a particular tumor to its clinical behavior. In ES/PNET, there appears to be a relationship between the molecular subtype of EWS/ETS fusion and patient survival (Fletcher, 1998; Zoubek et al., 1996) . Perhaps the same is true for secondary mutations as well. Preliminary clinical evidence suggests a correlation between loss of p16 and a poor clinical prognosis (Wei et al., 2000) . Even at a rate of 30%, deletion of p16 cannot be attributed to a random event suggesting that it provides a growth advantage. Future studies aimed at further assessing the impact that loss of p16, and other genetic events, on clinical outcomes should provide informative.
Materials and methods
Retroviral transduction and tissue culture
EWS/FLI1 and GFP constructs were cloned into the retroviral expression vector SRa-MSV and MSCV, respectively. TERT and E7 (gifts from R Weinberg) and SV40 large T antigen (gift from M Brown) were cloned into the pBabe-MSV retroviral vector. To produce retrovirus, these constructs were co-transfected with C-packaging plasmids into 293T Phoenix cells (a gift from G Nolan). High titre viral stocks were collected as conditioned media. Viral titres between MSCV-GFP and Sra-EWS/FLI1 were periodically tested in NIH3T3 cells and consistently found to be on the order of 5 ± 7610 6 cfu/ml. Both ecotropic and amphotropic virus was produced, reliant upon use of 293T Phoenix cells and C-packaging plasmids that expressed ecotropic or amphotropic envelope proteins. It was determined that viral titers could be boosted by cotransfection of viral packaging plasmids to augment the viral proteins already being expressed in Phoenix cells. No apparent replication competent virus was formed. This was determined by exposing p53 null MEFs to conditioned media from virally transduced MEF populations. No antibiotic resistant p53 null MEF colonies were observed.
Early passage normal or p16 de®cient MEFs (gifts from R DePinho), ARF de®cient MEFs (a gift from M Roussel), p53 de®cient MEFs (a gift from T Jacks), and primary human umbilical cord ®broblasts (a gift from T Triche) were maintained in 10% FCS/DMEM. Retroviral infection involved plating 2.5610 5 cells and adding 2.5 mls of appropriate viral supernatant. Cells were infected for 3 h at 378C. Productive infections were determined using FACS analysis to determine the number of cells expressing GFP protein 48 h post infection. Umbilical cord ®broblasts were serially infected with E7 and TERT, selection based on puromycin, and then EWS/FLI1, selection based on G418.
Immunoblot and Northern analysis
Protein lysates were collected at various time points postinfection (ranging between 2 days and 4 weeks), utilizing NP-40 lysis and centrifugation to remove nuclei. Primary antibodies used are polyclonal FLI-1 (Santa Cruz) and monoclonal a-tubulin (Sigma), the secondary antibodies used are goat-anti-rabbit and goat anti-mouse conjugated to horseradish peroxidase (Transduction Labs). Immune complexes were detected by chemiluminescence using commercial reagents (NEN). Total RNA was collected from umbilical ®broblasts and MEFs infected with E7, TERT, and SV40 immediately after drug selection. RNA was harvested using the STAT-60 reagent (Tel-TEST) according to manufacturer recommendations and employed in Northern experiments as previously described.
Proliferation and apoptosis assays
To determine the growth kinetics of MEFs infected with GFP or EWS/FLI1 retrovirus, 2.5610 5 cells were plated onto 10 cm dishes and infected with appropriate retrovirus. Cells were counted using trypan-blue exclusion and each time point was done in duplicate. Cells were counted every other day up Oncogene Loss of p16 complements EWS/FLI1 transformation B Deneen and CT Denny to 8 days post-infection. To quantitate the degree of cell death,¯oating and attached cells were collected 48 h postinfection and stained with propidium iodide (PI) in a 1X PBS solution. The degree of PI uptake is proportional to cell death and was determined using FACS. Apoptotic cells containing subdiploid DNA were quanti®ed by FACS analysis of PI-stained cells treated with a hypotonic cell solution. Caspase 3 activity in MEFs was determined by using the Ac-DEVD-AMC substrate essentially as described in (29). Protein lysates from retrovirally transduced MEFs were collected 48 h post-infection and incubated with the Ac-DEVD-AMC substrate. Caspase 3 cleaves the substrate after the aspartic acid (D) residue, thereby releasing the AMC group. The AMC becomes¯uorescent, and such¯uorescence is quantitated by FACS (excitation 380 nm, emission 440 nm).
Tumorigenesis assays
MEFs de®cient in p16, p53, or ARF were retrovirally transduced with EWS/FLI1 or GFP. In the experiments involving SV40, MEFs were serially infected with EWS/FLI1 and SV40. As before, FACS analysis of GFP expression was indicative of productive infection. Expression analysis of EWS/FLI1 and SV40 took place no later than 3 days before mouse injection. CB17 SCID mice were injected subcutaneously in the nape of the neck with 5610 6 cells. Mice were monitored until tumors were 1.5 cm in diameter at which time, the mice were sacri®ced and the tumor was removed by dissection. Tumor sections were placed in 10% buered formalin for paran-embedding and hemotoxylin and eosin staining. Tumor explant cell lines were created by plating minced/washed tumor tissue in 10% FCS/DMEM.
